We are delighted to announce that WuXi’s small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego. STA will provide process R&D and API manufacturing services for early phase clinical studies through its San Diego facility, and will have a highly experienced scientific and production team, better enabling our partners through added capacity, greater flexibility, and our customer-centric approach to drug development and manufacturing services.

Greater San Diego is one of the most innovative biopharma and biomedical hubs in the world, with more than 1,000 life sciences companies and more than 80 research institutes. WuXi has been serving the San Diego life sciences community since the very beginning with many collaborative partners.  This new facility further brings our comprehensive R&D services closer to our North American customers and partners in their efforts to improve patients’ lives.

Related Links:

  1. Official Press Release
  2. WuXi PharmaTech’s STA Subsidiary Receives First Approval from Japanese Regulatory Authorities
  3. WuXi AppTec’s STA Subsidiary Opens New Campus in Changzhou


  1. […] WuXi is thrilled to celebrate the life science industry’s continued vitality, including the U.S. FDA’s 22 approved drugs in 2016, with 16 from WuXi partners. This year, WuXi has been investing across the board, and we are expanding our global footprint, including in San Diego. WuXi’s presence in San Diego has grown tremendously over the past few years, including the recent acquisition of HD Biosciences, as well as opening an STA office. […]